PHARMACOLOGY RESEARCH FACULTY
Selected Publications
  • Berg, KA., Patwardhan, AM and Akopian, AN. (2012) Review: Receptor and Channel Heteromers as Pain Targets. Pharmaceuticals 5(3):249-278.
  • Berg, KA., Rowan, MP, Gupta, A., Sanchez, TA., Silva, M., Gomes, I., Portoghese, PS., Hargreaves, KM., Devi, LA. and Clarke, WP. (2012) Allosteric interactions between delta and kappa opioid receptors in peripheral sensory neurons. Mol Pharmacol 81:264-272.
  • Jeske, NA, Por, ED, Belugin, S., Chaudhury, S., Berg, KA., Akopian, A., Henry, M. and Gomez, R. (2011) AKAP150 mediates TRPV1 sensitivity to phosphatidylinositol-4, 5-bisphosphate. J. Neuroscience 31:8681-8688.
  • Gomez, R., Por, ED., Berg, KA., Clarke, WP., Glucksman, MJ. and Jeske, NA. (2011) Metallopeptidase inhibition potentiates bradykinin-induced hyperalgesia. Pain 152:1548-1554.
  • Berg, KA., Rowan, MP, Sanchez, TA, Silva, M., Patwardhan, AM., Milam, SB., Hargreaves, KM and Clarke, WP. (2011) Regulation of kappa-opioid receptor signaling in peripheral sensory neurons in vitro and in vivo. J. Pharmacol Exp Ther. 338:92-99.
  • Berg, KA. and Clarke, WP. (2010) Use of functional assays to detect and quantify functional selectivity. Drug Discovery Today: Technologies 7(1):e31-e36.
  • Rowan, MP., Berg, KA., Milam, SB., Jeske, NA., Roberts, JL., Hargreaves, KM and Clarke, WP. (2010) 17b-Estradiol rapidly enhances bradykinin signaling in primary sensory neurons in vitro and in vivo. J. Pharmacol Exp Ther. 335:190-196.
  • Aloyo, VJ., Berg, KA., Clarke, WP., Spampinato, U. and Harvey, JA. (2010) Inverse agonism at serotonin and cannabinoid receptors. Prog Mol Biol Transl Sci 91:1-40.
  • Aloyo, VJ., Berg, KA., Spampinato, U., Clarke, WP. and Harvey, JA. (2009) Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors. Pharmacol. Ther. 121:160-173.
  • Brea J., Castro, M., Giraldo, J., López-Giménez, JF, Padín, JF., QuintiÁn, F., Cadavid, MI., Vilaró, MT., Mengod, G., Berg, KA., Clarke, WP., Vilardaga, JP, Milligan, G. and Loza, MI. (2009) Evidence for distinct antagonist-revealed functional states of 5-hydroxytryptamine(2A) receptor homodimers. Mol Pharmacol 75:1380-1391.
  • Rowan, MP., Ruparel, NB., Patwardham, AM., Berg, KA., Clarke, WP. and Hargreaves, KM. (2009) Peripheral delta opioid receptors require priming for functional competence in vivo. Eur J Pharmacol. 602:283-287.
  • Berg, KA., Dunlop, J., Sanchez, T., Silva, M. and Clarke, WP. (2008) A conservative, single amino acid substitution in the second cytoplasmic domain of the h5-HT2C receptor alters both ligand-dependent and ligand-independent receptor signaling. J. Pharmacol Exp Ther. 324:1084-1092.
Kelly Berg
 

Kelly Berg

Associate Professor/Research
Ph.D., Department of Pharmacology
UTHSCSA
San Antonio, Texas

Office: 210-567-3528
Email: berg@uthscsa.edu

 
 

Keywords


G protein coupled receptors, signal transduction, ligand functional selectivity, constitutive receptor activity, opioids, serotonin, pain

 

Research Summary


Our work centers on questions concerning the molecular nature of drug efficacy and the mechanisms by which the efficacy of drugs can be regulated. Our current projects include studies on the regulation of opioid receptor agonist efficacy in primary sensory neurons, determination of the role of opioid receptor heteromers in peripheral mechanisms of analgesia and measurement of functional selectivity profiles of kappa opioid receptor ligands.

 

The management of pain represents a major medical and scientific challenge. Pain affects more Americans than diabetes, heart disease and cancer combined, yet it is one of the most poorly treated conditions in primary care and accounts for less than 1% of total NIH funding. Opioids represent a major drug class for the treatment of pain, however there are major drawbacks to their systemic use. In addition to serious adverse effects (e.g., dependence, tolerance, sedation), there are social and legal issues which limit their use. Consequently, there has been considerable interest in the peripheral analgesic effects of opioids since this approach may offer improved therapeutic outcomes. Currently we study mechanisms involved in the regulation of agonist efficacy at all three major opioid receptors, mu (MOR), delta (DOR) and kappa (KOR) receptor systems in primary (peripheral) sensory neurons. We utilize primary cultures of adult rat trigeminal ganglion neurons as well as rat behavioral models of peripheral nociception for these studies. The results of this work will lead to a better understanding of the cellular factors involved in regulating opioid agonist efficacy and may lead to novel approaches for the management of pain.

 

Originally thought to function only as receptor monomers, it is now known that G protein coupled receptors (GPCRs) also function as homo- and heterodimeric complexes (between different receptor subtypes) and perhaps even as higher order oligomers. GPCR heteromers have unique properties that make them attractive targets for pharmacotherapy. Among these are their limited cellular/tissue distribution (thereby improving drug selectivity) and allosteric interactions that occur between the receptor protomers that may be exploited to regulate function. Currently we study the function of opioid receptor heteromers in peripheral sensory neurons in culture and in rat behavioral models of peripheral nociception with the ultimate goal of identifying new pharmacological targets for improved pain therapy.

 

Ligand functional selectivity is a term used to describe the ability of drugs to differentially activate signaling cascades coupled to a single receptor subtype. The mechanism underlying functional selectivity is based upon the capacity of ligands with different chemical structures to promote different spectra of receptor protein conformations. Since these receptor conformations can interact differently with cellular signal transduction molecules (e.g. G proteins, ß-arrestins, etc.), the profile of cellular signaling produced is expected to differ for different ligands. Importantly, differences in the functional selectivity profile between drugs acting at the same receptor subtype may underlie differences in therapeutic efficacy and/or adverse effect liability. We were among the first to describe ligand functional selectivity for both agonists and inverse agonists which target serotonin receptors. Currently we are determining functional selectivity profiles for ligands which target kappa opioid receptors in primary sensory neurons.